In today’s briefing:
- Raffles Medical (RFMD SP): Stellar H1 Performance Driven by Resumption of Medical Tourism
Raffles Medical (RFMD SP): Stellar H1 Performance Driven by Resumption of Medical Tourism
- Raffles Medical (RFMD SP) reported strong H1 2022 results, with double-digit growth in revenue and net profit. With the resumption of international travel, the company is seeing increasing patients.
- While COVID-related revenue is declining, the company’s hospital business will benefit from the returning of foreign patients as well as resumption of elective surgeries for the domestic patients.
- Raffles Medical has received the approval to set up an IVF clinic in Hainan province of China.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
